Smart Money Circle

Guest:

Paul Warley CEO and President Ascent Solar Technologies

Website: https://ascentsolar.com

Ticker Symbol: ASTI

Bio:

Chief Executive Officer

Prior to Ascent, Warley was president of Warley & Company LLC, a strategic advisory firm from 2015 to 2022 – providing executive management services, capital advisory, and M&A to middle-market companies in the service, construction, technology, oil & gas, clean energy, food, retail and green-building sectors.

While at Warley & Company from 2018 to 2019, he was engaged as chief executive officer and CFO of 360Imaging, a provider of products and services for implant surgery and digital dentistry.

From 2011 to 2015, Warley served clients in the alternative energy industry as a managing director and chief compliance officer with Deloitte Corporate Finance.

From 1997 to 2011, Warley was managing director and region manager for GE Capital.

From 1984 to 1997, Warley served as senior vice president with Bank of America and Bankers Trust.

Company Bio:

Backed by 20+ years of R&D, 17 years of manufacturing experience, numerous awards, and a comprehensive IP and patent portfolio, Ascent Solar Technologies, Inc. (ASTI) is a leading provider of innovative, high-performance, flexible thin-film solar panels for use in scenarios where traditional rigid solar panels don’t work.

Ascent’s photovoltaic (PV) modules have been deployed on space missions, multiple airborne vehicles, agrivoltaic installations, in industrial and commercial construction, and in consumer goods, revolutionizing the use cases and environments for solar power.

Ascent Solar’s Headquarters & Perovskite Manufacturing Center of Excellence are located in Thornton, Colorado.

This CEO Is Using A.I. & Psychedelics To Improve Mental Health

Guest:

Kathryn Walker is the Founder CEO of Revitalist Lifestyle and Wellness -CSE CALM- RVLWF

Ticker: (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO)

Website:

https://revitalistclinic.com/

Bio:

About Kathryn Walker

Kathryn Walker is the CEO of Revitalist Lifestyle and Wellness (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) which serves as a leading mental health and wellness company led by a comprehensive team of specialty providers. Kathryn worked at a Level 1 Trauma Center in Tennessee for 9 years before attending anesthesia school at the University of North Carolina-Charlotte. She practiced anesthesia of all specialties for 8 years before opening the first Revitalist location in Knoxville, TN in 2018. Today Kathryn operates as a leading advocate for psychedelic medicine as she continues to advance her comprehensive skill set recently graduating with her second Master's degree in Psychiatric Nursing as a Psychiatric Mental Health Nurse Practitioner.

Recognizing the need for community access, Kathryn founded the national mental health 501c3 nonprofit, Community Change Foundation (CommunityChangeFoundation.org). This nonprofit foundation focuses on providing financial assistance to veterans, frontline workers, and the financially disadvantaged seeking help with psychedelic therapies. Kathryn incorporated the Community Change Foundation in 2019.

Recognizing the need for education and training advancements, Kathryn founded the American Association of Psychedelics (AAPsychedelics.org). This education non-profit 501c3 aims to continually bring high quality education and training to all disciplines of providers. Kathryn incorporated the American Association of Psychedelics in 2021.

Kathryn is the Academic Detailer for the MetroDrug Coalition, she sits on the board for American Association of Psychedelics, Mental Health Association of East Tennessee, Herzig University, and Women in Psychedelics.

About Company

About Revitalist Lifestyle and Wellness Ltd. Revitalist (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) is a mental health and wellness company focused on comprehensive care in the ketamine wellness space offering innovative, evidenced-based services. The Company, through its subsidiary Revitalist, operates physical locations and virtual offices across 35 states.

Founded and led by Kathryn Walker, an advanced provider in the psychedelic space, Revitalist is at the forefront of this emerging field.

Guest:

Dr. Lynn Kirkpatrick Chief Executive Officer, Ensysce Biosciences Inc.

Ticker: $ENSC (NASDAQ)

Website:

https://ensysce.com/

Bio:

Dr. Lynn Kirkpatrick

Chief Executive Officer, Ensysce Biosciences Inc.

Dr. Kirkpatrick has focused her entire career on drug discovery and development. Former Professor of Chemistry and Biochemistry in Canada, she has been active in both the novel drug discovery as well as clinical development of drug candidates throughout her career. She co-founded three start-up companies and successfully brought three novel cancer drug candidates and two other drug candidates in pain and infectious diseases from bench into human clinical trials.

Following the acquisition of the first company she co-founded, ProlX Pharmaceuticals, she became President and CEO of Ensysce Biosciences Inc. and took the company public in 2021. Now Dr. Kirkpatrick is guiding the clinical development of Ensysce’s highly novel pain products, which use compelling chemical approaches to reduce abuse and overdose potential. Dr. Kirkpatrick received her PhD in Medicinal Chemistry from the University of Saskatchewan and completed a post-doctoral fellowship in Pharmacology at Yale University School of Medicine before returning to Canada where she spent 16 years in academia.

She has published extensively in the area of targeted cancer drug discovery and development and holds numerous patents for novel drug candidates.

Company Bio:

Ensysce Biosciences is developing first-in-class and uniquely innovative solutions in oral drug delivery. Our proprietary TAAP™ and MPAR® technologies improve the care and safety of patients by preventing the possibility of both abuse and overdose of prescription drugs. Our mission is to revolutionize the safety and oral delivery of medicines for areas of high unmet need.

This Biotech CEO Is Using Neuroplastogenic Small-Molecule Therapeutics To Create Next Generation Mental Health. Dr Joseph Tucker – CEO Enveric $ENVB

Guest:

Dr. Joseph Tucker – CEO – Enveric Biosciences

Website:

https://www.enveric.com/

Company Bio:

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Dr. Tucker Bio:

Dr. Tucker is a seasoned executive who has built several publicly traded biotechnology companies. Dr. Tucker was a founder and Chief Executive Officer of Stem Cell Therapeutics, which he took public on the TSX (TSX: SSS). Trillium Therapeutics (NASDAQ: TRIL, TSX: TRIL) acquired Stem Cell Therapeutics in 2013. Dr. Tucker has also held the position of Co-Founder and Chief Executive Officer of Epimeron Inc., a University of Calgary start-up acquired in the creation of Willow Biosciences Inc. (TSX: WLLW). At Willow, Dr. Tucker served as Executive Chairman and Chief Operating Officer. Prior to founding companies, Dr. Tucker was a healthcare analyst with two investment banks and has also worked in technology commercialization for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.

This CEO Is Using Alpaca DNA To Fight Inflammation & A Lot More! CEO Scinai… Nasdaq $SCNI

How This CEO Is Revolutionizing The Smart Eyewear Market… Innovative Eyewear CEO & Founder - $LUCY

Guest: Harrison Gross Founder & CEO Innovative Eyewear $LUCY

Ticker: LUCY

Website: https://lucyd.co/

Bio:

CEO & COFOUNDER HARRISON GROSS

Harrison Gross is one of the founders of Innovative Eyewear and has served as our Chief Executive Officer and as a director since August 2019, where he guides the company’s product and brand development.

Prior to his employment at Innovative Eyewear, from August 2017 to August 2019, Mr. Gross served in various positions, including chief executive officer and media & UX lead, of Lucyd Ltd., our largest stockholder and the licensor of our technology which is also a smart eyewear development company where he developed the company’s brand identity and oversaw general operations and product development.

Additionally, from November 2015 to August 2021, Mr. Gross served as the Digital Media Manager of Tekcapital PLC (“Tekcapital”) (LON: TEK), a university intellectual property investment firm that is the parent company of Tekcapital Europe Limited, and Lucyd Ltd, the holding company for Tekcapital’s shares in Innovative Eyewear, where he created, developed and marketed for the company’s licensed properties.

Prior to that, from October 2013 to September 2014, Mr. Gross worked as a credit analyst for a Verizon, Inc. contractor, where he managed credit systems and provided support to Verizon agents.

Mr. Gross is a graduate of Columbia University with a BA in Writing and received a BA in Jewish Studies from the Jewish Theological Seminary. Mr. Gross is well qualified to serve as a director due to his substantial knowledge of our products, being a named inventor of most of the Company’s patents and his experience in marketing, product and app development.

Never Stop Learning With IoT Pioneer David  Ly Founder & CEO Iveda – $IVDA

Ticker: $IVDA (Nasdaq)

Website: https://iveda.com/

Bio:

David Ly is the visionary leader and founder of Iveda. David

This CEO is Disrupting Hospitals - Dr. Tom Vo- CEO and Founder Nutex Health - $NUTX

Guest: Dr. Tom Vo CEO and Founder Nutex Health $ NUTX

Website:

https://www.nutexhealth.com/

Bio:

Tom Vo, M.D., MBA Chairman of the Board and Chief Executive Officer Since 2010, Dr. Vo has served as the founder and executive officer of the Nutex Entities, which operates a network of micro-hospitals that provide comprehensive and high-quality 24/7 care‎ throughout the United States. Although no longer practicing, Dr. Vo worked as an emergency medicine physician in Houston, Texas, for over twenty years. Between 2008 and 2011, Dr. Vo served as a founder and original partner at the free-standing emergency health company, Neighbors Emergency Center. Since then, Dr. Vo has been involved with the opening of over 40 FSEDs and Micro Hospitals. Dr. Vo holds a bachelor’s degree in Life Sciences from Kent State University and received his M.D. from Northeastern Ohio Universities College of Medicine. In 2004, Dr. Vo also received his MBA from Rice University. The Company believes that Dr. Vo’s unique background in the emergency hospital field and proven management experience make him well qualified to serve as a director.

This CEO Is Fighting Inflammation – Sea Star Medical -$ICU- CEO, Eric Schlorff, Shares Timeless Advice

Guest: Eric Schlorff has served as the Chief Executive Officer of SeaStar Medical

Ticker: $ICU

Website: https://seastarmedical.com/

Sea Star Medical YouTube: / @seastarmed

Bio:

Since 2019, Eric Schlorff has served as the Chief Executive Officer of SeaStar Medical, responsible for the management, strategy, and operations of the company. He has extensive experience in financial planning and managing large, complex organizations and as well as deep knowledge of SeaStar Medical’s business operations, including the scientific basis, regulatory requirements and sales and marketing channels.

Prior to joining SeaStar Medical in 2016, Mr. Schlorff spent more than 20 years at Dow Chemical Company, serving in served in multiple role, including Global Director of Alternative Investments for the Dow Chemical Pension Plan, Global Finance Leader for Crop Protection & Seeds at Dow AgroSciences, Global Market Intelligence Leader at Dow AgroSciences, Global Financial Manager of Royalties at Dow Agrosciences, Senior Investment Manager of Alternative Investments at Dow Chemical Company, New Business Development of Pharmaceuticals at Dow Chemical Company, Global Financial Analyst within the New Businesses division at Dow Chemical Company, and Global Financial Analyst within Dow AgroSciences at Dow Chemical Company.

Mr. Schlorff has a bachelor’s degree in chemistry and biology from Mac Murray College, an M.S. in pharmacology from Southern Illinois University School of Medicine and a master’s in business administration from University of Illinois Urbana-Champaign.